LCZ696 (Angiotensin–Neprilysin Inhibition): The New Kid on the Heart Failure Block?

Angiotensin-converting enzyme inhibitors (ACEIs) have been the cornerstone in systolic heart failure (HF) regimens over the past 25 years. Their ability to block the renin–angiotensin–aldosterone system and their vasodilatory properties has repeatedly been shown to lower morbidity and mortality in p...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of pharmacy practice 2015-04, Vol.28 (2), p.137-145
Hauptverfasser:	Pham, Antony Q., Patel, Yesha, Gallagher, Brittany
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminobutyrates - pharmacokinetics Aminobutyrates - pharmacology Aminobutyrates - therapeutic use Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Animals Drug Combinations Heart Failure - drug therapy Humans Rats Tetrazoles - pharmacokinetics Tetrazoles - pharmacology Tetrazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!